XNCRXencor Inc
Pharmaceutical Preparations
- Revenue
- $126M
- 14% YoY
- Operating margin
- -141.4%
- 12% YoY
- EBITDA
- −$167M
- 0.4% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $33M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired34% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $275M | $165M | $175M | $110M | $126M | 14% |
| Operating income | $44M | −$82M | −$132M | −$178M | −$178M | 0.5% |
| Net income | $83M | −$55M | −$133M | −$233M | −$92M | 60% |
| Operating cash flow | −$17M | $24M | −$78M | −$202M | −$135M | 33% |
| Capex | $13M | $38M | $18M | $6M | $3M | 48% |
| Stock-based comp | $37M | $49M | $54M | $53M | $43M | 19% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $28K · 1
- Net
- −$28K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | $1M | 35 | 120 |
| FY2024 | $7M | $3M | 53 | 91 |
| FY2023 | $8M | $6M | 49 | 92 |
| FY2022 | $8M | −$771K | 60 | 89 |
| FY2021 | $5M | $317K | 92 | 99 |